rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2020-469-479rsp-2948Research ArticleПЕРЕДОВАЯLEADING ARTICLEКоронавирусная болезнь 2019 (COVID-19) у детей: уроки педиатрической ревматологииCoronavirus Desease 2019 (COVID-19) in Children: Lessons from Pediatric Rheumatologyhttps://orcid.org/0000-0002-0513-6826КаледаМ. И.KaledaM. I.

Каледа Мария Игоревна

115522, Москва, Каширское шоссе, 34а

Kaleda Maria

115522, Moscow, Kashirskoe highway, 34A

kaleda-mi@yandex.ruhttps://orcid.org/0000-0003-1842-0348НикишинаИ. П.NikishinaI. P.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoe highway, 34A

https://orcid.org/0000-0003-2671-1655ФедоровЕ. С.FedorovE. S.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoe highway, 34A

https://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

115522, Москва, Каширское шоссе, 34а119991, Москва, ул. Трубецкая, 8, стр. 2

115522, Moscow, Kashirskoe highway, 34A119991, Moscow, Trubetskaya str., 8/2

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University (Sechenov University) of the Ministry of Health of RussiaRussian Federation202009112020585469479Copyright © Каледа М.И., Никишина И.П., Федоров Е.С., Насонов Е.Л., 20202020Каледа М.И., Никишина И.П., Федоров Е.С., Насонов Е.Л.Kaleda M.I., Nikishina I.P., Fedorov E.S., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2948

Клиническая картина и исходы коронавирусной болезни 2019 (coronavirus disease – COVID-19) зависят от многих факторов, одним из которых является возраст пациента. Одним из тяжелых жизнеугрожающих проявлений у взрослых является острый респираторный дистресс-синдром (ОРДС), в ряде случаев сопровождающийся развитием полиорганной недостаточности. В течение первых месяцев пандемии COVID-19 сложилось мнение, что у детей это заболевание, как правило, протекает в легкой форме и не приводит к летальному исходу. Однако по мере накопления новых сведений стала очевидной возможность тяжелого течения COVID-19 у детей, приводящего к развитию патологии, получившей название «мультисистемный воспалительный синдром» (Multisystem inflammatory syndrome in children – MIS-C). В статье обсуждаются эпидемиологические, клинические и лабораторные характеристики MIS-C, подходы к дифференциальной диагностике с другими воспалительными заболеваниями у детей, предполагаемые механизмы иммунопатогенеза и перспективы фармакотерапии.

The clinical presentation and outcomes of infection with the novel coronavirus (COVID-19) are characterized by exceptional variability in manifestations, which depend on many factors, one of which is the patient’s age. One of the severe life-threatening manifestations in adults is severe acute respiratory syndrome (SARS-CoV-2), in some cases accompanied by the development of multiple organ failure. During the first two to three months of the COVID-19 pandemic, the global medical community was of the opinion that this disease in children is usually mild and not fatal. However, with the accumulation of new information, it became clear that there is a growing recognition of the existence of multisystem inflammatory syndrome in children, chronologically associated with SARS-CoV-2, which can lead to serious consequences. The article presents the main epidemiological, clinical and laboratory characteristics of the syndrome, as well as discusses the issues of its pathogenesis, differential diagnosis with a number of other acute conditions associated with an dysbalance of cytokines.

коронавирусная болезнь 2019 (COVID-19)мультисистемный воспалительный синдром у детейболезнь КавасакиCOVID-19multisystem inflammatory syndrome in children (MIS-C)Kawasaki diseaseReferencesWiersinga W.J., Rhodes A., Cheng A.C., Peacock S.J., Prescott H.C. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324(8):782–793. DOI: 10.1001/jama.2020.12839Wiersinga W.J., Rhodes A., Cheng A.C., Peacock S.J., Prescott H.C. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324(8):782–793. DOI: 10.1001/jama.2020.12839Jiang L., Tang K., Levin M., et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020:S1473-3099(20)30651-4. DOI: 10.1016/S1473-3099(20)30651-4Jiang L., Tang K., Levin M., et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020:S1473-3099(20)30651-4. DOI: 10.1016/S1473-3099(20)30651-4Насонов Е.Л. Коронавирусная болезнь 2019 (COVID-19): размышления ревматолога. Научно-практическая ревматология. 2020;58(2):123–132. DOI: 10.14412/1995-4484-2020-123-132Nasonov E.L. Coronavirus disease 2019 (COVID-19): a rheumatologist`s thoughts. Nauchnoprakticheskaya revmatologiya = Rheumatology Science and Practice. 2020;58(2):123–132 (In Russ.). DOI: 10.14412/1995-4484-2020-123-132Методические рекомендации: особенности клинических проявлений и лечения заболевания, вызванного новой коронавирусной инфекцией (COVID-19) у детей. Версия 2 от 03.07.2020. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/050/914/original/03062020_дети_COVID-19_v2.pdfMethodical recommendations: features of clinical manifestations and treatment of the disease caused by a new coronavirus infection (COVID-19) in children. Version 2 from 03/07/2020 (In Russ.). URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/050/914/original/03062020_дети_COVID-19_v2.pdfSteinman J.B., Lum F.M., Pui-Kay Ho P., Kaminski N., Steinman L. Reduced development of COVID-19 in children reveals molecular checkpoints gating pathogenesis illuminating potential therapeutics. Proc Nat Acad Sci, 202012358. DOI: 10.1073/pnas.2012358117Steinman J.B., Lum F.M., Pui-Kay Ho P., Kaminski N., Steinman L. Reduced development of COVID-19 in children reveals molecular checkpoints gating pathogenesis illuminating potential therapeutics. Proc Nat Acad Sci, 202012358. DOI: 10.1073/pnas.2012358117Fialkowski A., Gernez Y., Arya P., Weinacht K.G., Kinane T.B., Yonker L.M. Insight into the pediatric and adult dichotomy of COVID-19: Age-related differences in the immune response to SARS-CoV-2 infection. Pediatr Pulmonol. 2020. DOI: 10.1002/ppul.24981Fialkowski A., Gernez Y., Arya P., Weinacht K.G., Kinane T.B., Yonker L.M. Insight into the pediatric and adult dichotomy of COVID-19: Age-related differences in the immune response to SARS-CoV-2 infection. Pediatr Pulmonol. 2020. DOI: 10.1002/ppul.24981WHO. Multisystem inflammatory syndrome in children and adolescents with COVID-19. URL: https://www.who.int/publications/i/item/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19 (Date accessed: 2020).WHO. Multisystem inflammatory syndrome in children and adolescents with COVID-19. URL: https://www.who.int/publications/i/item/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19 (Date accessed: 2020).Centers for Disease Control and Prevention. Multisystem inflammatory syndrome. URL: https://www.cdc.gov/mis-c/hcp/ (Date accessed: 2020).Centers for Disease Control and Prevention. Multisystem inflammatory syndrome. URL: https://www.cdc.gov/mis-c/hcp/ (Date accessed: 2020).The Royal College of Paediatrics and Child Health. Guidancepaediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS). URL: https://www.rcpch.ac.uk/resources/guidance-paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19-pims (Date accessed: 2020).The Royal College of Paediatrics and Child Health. Guidancepaediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS). URL: https://www.rcpch.ac.uk/resources/guidance-paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19-pims (Date accessed: 2020).Nakra N.A., Blumberg D.A., Herrera-Guerra A., Lakshminrusimha S. Multi-System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management. Children (Basel). 2020;7(7):69. DOI: 10.3390/children7070069. PMID: 32630212. PMCID: PMC7401880Nakra N.A., Blumberg D.A., Herrera-Guerra A., Lakshminrusimha S. Multi-System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management. Children (Basel). 2020;7(7):69. DOI: 10.3390/children7070069. PMID: 32630212. PMCID: PMC7401880Koné-Paut I., Cimaz R. Is it Kawasaki shock syndrome, Kawasaki-like disease or pediatric inflammatory multisystem disease? The importance of semantic in the era of COVID-19 pandemic. RMD Open. 2020;6(2):e001333. DOI: 10.1136/rmdopen-2020-001333Koné-Paut I., Cimaz R. Is it Kawasaki shock syndrome, Kawasaki-like disease or pediatric inflammatory multisystem disease? The importance of semantic in the era of COVID-19 pandemic. RMD Open. 2020;6(2):e001333. DOI: 10.1136/rmdopen-2020-001333Loke Y.H., Berul C.I., Harahsheh A.S. Multisystem inflammatory syndrome in children: Is there a linkage to Kawasaki disease? Trends Cardiovasc Med. 2020;30(7):389–396. DOI: 10.1016/j.tcm.2020.07.004Loke Y.H., Berul C.I., Harahsheh A.S. Multisystem inflammatory syndrome in children: Is there a linkage to Kawasaki disease? Trends Cardiovasc Med. 2020;30(7):389–396. DOI: 10.1016/j.tcm.2020.07.004Henderson L.A., Cron R.Q. Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management. Paediatr Drugs. 2020;22(1):29–44.Henderson L.A., Cron R.Q. Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management. Paediatr Drugs. 2020;22(1):29–44.Dufort E.M., Koumans E.H., Chow E.J., et al. Multisystem Inflammatory Syndrome in Children in New York State. N Engl J Med. 2020;383:347–358. DOI: 10.1056/NEJMoa2021756Dufort E.M., Koumans E.H., Chow E.J., et al. Multisystem Inflammatory Syndrome in Children in New York State. N Engl J Med. 2020;383:347–358. DOI: 10.1056/NEJMoa2021756Levin M. Childhood Multisystem Inflammatory Syndrome A New Challenge in the Pandemic. N Engl J Med. 2020;383(4):393–395. DOI: 10.1056/NEJMe2023158Levin M. Childhood Multisystem Inflammatory Syndrome A New Challenge in the Pandemic. N Engl J Med. 2020;383(4):393–395. DOI: 10.1056/NEJMe2023158Cheung E.W., Zachariah P., Gorelik M., et al. Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City. JAMA. 2020;e2010374. DOI: 10.1001/jama.2020.10374Cheung E.W., Zachariah P., Gorelik M., et al. Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City. JAMA. 2020;e2010374. DOI: 10.1001/jama.2020.10374Feldstein L.R., Rose E.B., Horwitz S.M., et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020;383(4):334–346. DOI: 10.1056/NEJMoa2021680Feldstein L.R., Rose E.B., Horwitz S.M., et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020;383(4):334–346. DOI: 10.1056/NEJMoa2021680Ahmed M., Advani S., Moreira A., et al. Multisystem inflammatory syndrome in children: A systematic review [published online ahead of print, 2020]. EClinicalMedicine. 2020;100527. DOI: 10.1016/j.eclinm.2020.100527Ahmed M., Advani S., Moreira A., et al. Multisystem inflammatory syndrome in children: A systematic review [published online ahead of print, 2020]. EClinicalMedicine. 2020;100527. DOI: 10.1016/j.eclinm.2020.100527Radia T., Williams N., Agrawal P., Harman K., Weale J., et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C): A systematic review of clinical features and presentation. Paediatr Respir Rev. 2020:S1526-0542(20)30117-2. DOI: 10.1016/j.prrv.2020.08.001.Radia T., Williams N., Agrawal P., Harman K., Weale J., et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C): A systematic review of clinical features and presentation. Paediatr Respir Rev. 2020:S1526-0542(20)30117-2. DOI: 10.1016/j.prrv.2020.08.001.Abrams J.Y., Godfred-Cato S.E., Oster M.E., et al. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2: A Systematic Review. J Pediatr. 2020;S00223476(20)30985-9. DOI: 10.1016/j.jpeds.2020.08.003Abrams J.Y., Godfred-Cato S.E., Oster M.E., et al. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2: A Systematic Review. J Pediatr. 2020;S00223476(20)30985-9. DOI: 10.1016/j.jpeds.2020.08.003Hoste L., Van Paemel R., Haerynck F. Multisystem inflammatory syndrome in children related to COVID-19: A systematic review medRxiv. 2020.08.17.20173641. DOI: 10.1101/2020.08.17.20173641Hoste L., Van Paemel R., Haerynck F. Multisystem inflammatory syndrome in children related to COVID-19: A systematic review medRxiv. 2020.08.17.20173641. DOI: 10.1101/2020.08.17.20173641Aronoff S.C., Hall A., Del Vecchio M.T. The Natural History of Severe Acute Respiratory Syndrome Coronavirus 2–Related Multisystem Inflammatory Syndrome in Children: A Systematic Review. J Pediatric Infec Dis Soc, 2020, piaa112. DOI: 10.1093/jpids/piaa112Aronoff S.C., Hall A., Del Vecchio M.T. The Natural History of Severe Acute Respiratory Syndrome Coronavirus 2–Related Multisystem Inflammatory Syndrome in Children: A Systematic Review. J Pediatric Infec Dis Soc, 2020, piaa112. DOI: 10.1093/jpids/piaa112Godfred-Cato S., Bryant B., Leung J., et al. COVID-19Associated Multisystem Inflammatory Syndrome in Children United States, March-July 2020. MMWR Morb Mortal Wkly Rep. 2020;69(32):1074–1080. Published 2020. DOI: 10.15585/mmwr.mm6932e2Godfred-Cato S., Bryant B., Leung J., et al. COVID-19Associated Multisystem Inflammatory Syndrome in Children United States, March-July 2020. MMWR Morb Mortal Wkly Rep. 2020;69(32):1074–1080. Published 2020. DOI: 10.15585/mmwr.mm6932e2Rowley A.H. Multisystem Inflammatory Syndrome in Children and Kawasaki Disease: Two Different Illnesses with Overlapping Clinical Features. J Pediatr. 2020;224:129–132. DOI: 10.1016/j.jpeds.2020.06.057Rowley A.H. Multisystem Inflammatory Syndrome in Children and Kawasaki Disease: Two Different Illnesses with Overlapping Clinical Features. J Pediatr. 2020;224:129–132. DOI: 10.1016/j.jpeds.2020.06.057McCrindle B.W., Rowley A.H., Newburger J.W., et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation. 2017;135(17):e927-e999. DOI: 10.1161/CIR.0000000000000484. Erratum in: Circulation. 2019;140(5):e181–e184.McCrindle B.W., Rowley A.H., Newburger J.W., et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation. 2017;135(17):e927-e999. DOI: 10.1161/CIR.0000000000000484. Erratum in: Circulation. 2019;140(5):e181–e184.Elakabawi K., Lin J., Jiao F., Guo N., Yuan Z. Kawasaki Disease: Global Burden and Genetic Background. Cardiol Res. 2020;11(1):9–14. DOI: 10.14740/cr993Elakabawi K., Lin J., Jiao F., Guo N., Yuan Z. Kawasaki Disease: Global Burden and Genetic Background. Cardiol Res. 2020;11(1):9–14. DOI: 10.14740/cr993Jhaveri S., Ahluwalia N., Kaushik S., et al. Longitudinal Echocardiographic Assessment of Coronary Arteries and Left Ventricular Function following Multisystem Inflammatory Syndrome in Children. J Pediatr. 2020;S0022-3476(20)30984-7. DOI: 10.1016/j.jpeds.2020.08.002Jhaveri S., Ahluwalia N., Kaushik S., et al. Longitudinal Echocardiographic Assessment of Coronary Arteries and Left Ventricular Function following Multisystem Inflammatory Syndrome in Children. J Pediatr. 2020;S0022-3476(20)30984-7. DOI: 10.1016/j.jpeds.2020.08.002Muniz J.C., Dummer K., Gauvreau K., Colan S.D., Fulton D.R., Newburger J.W. Coronary artery dimensions in febrile children without Kawasaki disease. Circ Cardiovasc Imaging. 2013 Mar 1;6(2):239–244. DOI: 10.1161/CIRCIMAGING.112.000159Muniz J.C., Dummer K., Gauvreau K., Colan S.D., Fulton D.R., Newburger J.W. Coronary artery dimensions in febrile children without Kawasaki disease. Circ Cardiovasc Imaging. 2013 Mar 1;6(2):239–244. DOI: 10.1161/CIRCIMAGING.112.000159Fox S.E., Lameira F.S., Rinker E.B., Vander Heide R.S. Cardiac Endotheliitis and Multisystem Inflammatory Syndrome After COVID-19. Ann Intern Med. 2020:L20-0882. DOI: 10.7326/L20-0882Fox S.E., Lameira F.S., Rinker E.B., Vander Heide R.S. Cardiac Endotheliitis and Multisystem Inflammatory Syndrome After COVID-19. Ann Intern Med. 2020:L20-0882. DOI: 10.7326/L20-0882Fox S.E., Akmatbekov A., Harbert J.L., Li G., Quincy Brown J., Vander Heide R.S. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med. 2020;8(7):681–686. DOI: 10.1016/S2213-2600(20)30243-5Fox S.E., Akmatbekov A., Harbert J.L., Li G., Quincy Brown J., Vander Heide R.S. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med. 2020;8(7):681–686. DOI: 10.1016/S2213-2600(20)30243-5Dolhnikoff M., Ferreira Ferranti J., de Almeida Monteiro R.A., et al. SARS-CoV-2 in cardiac tissue of a child with COVID-19related multisystem inflammatory syndrome. Lancet Child Adolesc Health. 2020;4(10):790–794. DOI: 10.1016/S23524642(20)30257-1. Erratum in: Lancet Child Adolesc Health. 2020;4(10):e39.Dolhnikoff M., Ferreira Ferranti J., de Almeida Monteiro R.A., et al. SARS-CoV-2 in cardiac tissue of a child with COVID-19related multisystem inflammatory syndrome. Lancet Child Adolesc Health. 2020;4(10):790–794. DOI: 10.1016/S23524642(20)30257-1. Erratum in: Lancet Child Adolesc Health. 2020;4(10):e39.Verdoni L., Mazza A., Gervasoni A., et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020. Epub ahead of print. DOI: 10.1016/S0140-6736(20)31103-XVerdoni L., Mazza A., Gervasoni A., et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020. Epub ahead of print. DOI: 10.1016/S0140-6736(20)31103-XRowley A.H., Shulman S.T., Arditi M. Immune pathogenesis of COVID-19-related Multisystem Inflammatory Syndrome in Children (MIS-C). J Clin Invest. 2020. DOI: 10.1172/JCI143840Rowley A.H., Shulman S.T., Arditi M. Immune pathogenesis of COVID-19-related Multisystem Inflammatory Syndrome in Children (MIS-C). J Clin Invest. 2020. DOI: 10.1172/JCI143840Rowley A.H. Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children. Nat Rev Immunol. 2020(8):453–454. DOI: 10.1038/s41577-020-0367-5Rowley A.H. Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children. Nat Rev Immunol. 2020(8):453–454. DOI: 10.1038/s41577-020-0367-5Henderson L.A., Canna S.W., Schulert G.S., et al. On the alert for cytokine storm: Immunopathology in COVID-19. Arthritis Rheum. 2020. DOI: 10.1002/art.41285Henderson L.A., Canna S.W., Schulert G.S., et al. On the alert for cytokine storm: Immunopathology in COVID-19. Arthritis Rheum. 2020. DOI: 10.1002/art.41285Nasonov E., Samsonov M. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. Biomed Pharmacother. 2020;131:110698. DOI: 10.1016/j.biopha.2020.110698Nasonov E., Samsonov M. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. Biomed Pharmacother. 2020;131:110698. DOI: 10.1016/j.biopha.2020.110698Carter S.J., Tattersall R.S., Ramanan A.V. Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. Rheumatology (Oxford). 2019;58(1):5–17. DOI: 10.1093/rheumatology/key006Carter S.J., Tattersall R.S., Ramanan A.V. Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. Rheumatology (Oxford). 2019;58(1):5–17. DOI: 10.1093/rheumatology/key006Behrens E.M., Koretzky G.A. Review: Cytokine storm syndrome: looking toward the precision medicine era. Arthritis Rheum. 2017;69(6):1135–1143. DOI: 10.1002/art.40071Behrens E.M., Koretzky G.A. Review: Cytokine storm syndrome: looking toward the precision medicine era. Arthritis Rheum. 2017;69(6):1135–1143. DOI: 10.1002/art.40071Насонов Е.Л., Бекетова Т.В., Решетняк Т.М., Лила А.М., Ананьева Л.П., Лисицина Т.А., Соловьев С.К. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания: на перекрестке проблем тромбовоспаления и аутоиммунитета. Научнопрактическая ревматология. 2020;58(4):353–367. DOI: 10.47360/1995-4484-2020-353-367Nasonov E.L., Beketova T.V., Reshetnyak T.M., Lila A.M., Ananieva L.P., Lisitsyna T.A., Soloviev S.K. Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2020;58(4):353–367 (In Russ.). DOI: 10.47360/1995-4484-2020-353-367Merrill J.T., Erkan D., Winakur J., James J.A. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat Rev Rheumatol. 2020;16(10):581–589. DOI: 10.1038/s41584-020-0474-5Merrill J.T., Erkan D., Winakur J., James J.A. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat Rev Rheumatol. 2020;16(10):581–589. DOI: 10.1038/s41584-020-0474-5Ramos-Casals M., Brito-Zeron P., Lopez-Guillermo A., et al. Adult haemophagocytic syndrome. Lancet. 2014;383:1503–1516. DOI: 10.1016/S0140-6736(13)61048-XRamos-Casals M., Brito-Zeron P., Lopez-Guillermo A., et al. Adult haemophagocytic syndrome. Lancet. 2014;383:1503–1516. DOI: 10.1016/S0140-6736(13)61048-XJunior H.S., Sakano T.M.S., Rodrigues R.M., et al. Multisystem inflammatory syndrome associated with COVID-19 from the pediatric emergency physician’s point of view. J Pediatr (Rio J). 2020;S0021-7557(20)30203-5. DOI: 10.1016/j.jped.2020.08.004Junior H.S., Sakano T.M.S., Rodrigues R.M., et al. Multisystem inflammatory syndrome associated with COVID-19 from the pediatric emergency physician’s point of view. J Pediatr (Rio J). 2020;S0021-7557(20)30203-5. DOI: 10.1016/j.jped.2020.08.004Wang Z., Wang Y., Huang W., et al. Hemophagocytic Lymphohistiocytosis Is Not Only a Childhood Disease: A MultiCenter Study of 613 Cases from Chinese HLH Workgroup. Blood 2014;124(21):4146. DOI: 10.1182/blood.V124.21.4146.4146Wang Z., Wang Y., Huang W., et al. Hemophagocytic Lymphohistiocytosis Is Not Only a Childhood Disease: A MultiCenter Study of 613 Cases from Chinese HLH Workgroup. Blood 2014;124(21):4146. DOI: 10.1182/blood.V124.21.4146.4146Halyabar O., Chang M.H., Schoettler M.L., et al. Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome. Pediatr Rheumatol Online J. 2019;17(1):7. DOI: 10.1186/s12969-019-0309-6Halyabar O., Chang M.H., Schoettler M.L., et al. Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome. Pediatr Rheumatol Online J. 2019;17(1):7. DOI: 10.1186/s12969-019-0309-6Tanner T., Wahezi D.M. Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19. Paediatr Respir Rev. 2020;35:81–87. DOI: 10.1016/j.prrv.2020.07.003Tanner T., Wahezi D.M. Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19. Paediatr Respir Rev. 2020;35:81–87. DOI: 10.1016/j.prrv.2020.07.003Perez-Toledo M., Faustini S.E., Jossi S.E., et al. Serology confirms SARS-CoV-2 infection in PCR-negative children presenting with Paediatric Inflammatory Multi-System Syndrome. medRxiv. 2020:2020.06.05.20123117. DOI: 10.1101/2020.06.05.20123117Perez-Toledo M., Faustini S.E., Jossi S.E., et al. Serology confirms SARS-CoV-2 infection in PCR-negative children presenting with Paediatric Inflammatory Multi-System Syndrome. medRxiv. 2020:2020.06.05.20123117. DOI: 10.1101/2020.06.05.20123117Anderson E.M., Diorio C., Goodwin E.C., et al. SARS-CoV-2 antibody responses in children with MIS-C and mild and severe COVID-19. medRxiv. 2020;2020.08.17.20176552. Published 2020. DOI: 10.1101/2020.08.17.20176552Anderson E.M., Diorio C., Goodwin E.C., et al. SARS-CoV-2 antibody responses in children with MIS-C and mild and severe COVID-19. medRxiv. 2020;2020.08.17.20176552. Published 2020. DOI: 10.1101/2020.08.17.20176552Weisberg S.P., Connors T., Zhu Y., et al. Antibody responses to SARS-CoV2 are distinct in children with MIS-C compared to adults with COVID-19. medRxiv 2020.07.12.20151068. DOI: 10.1101/2020.07.12.20151068Weisberg S.P., Connors T., Zhu Y., et al. Antibody responses to SARS-CoV2 are distinct in children with MIS-C compared to adults with COVID-19. medRxiv 2020.07.12.20151068. DOI: 10.1101/2020.07.12.20151068Sette A., Crotty S. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. Nat Rev Immunol. 2020;20(8):457–458. DOI: 10.1038/s41577-020-0389-z. Erratum in: Nat Rev Immunol. 2020 Oct;20(10):644.Sette A., Crotty S. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. Nat Rev Immunol. 2020;20(8):457–458. DOI: 10.1038/s41577-020-0389-z. Erratum in: Nat Rev Immunol. 2020 Oct;20(10):644.Cheng M.H., Zhang S., Porritt R.A., Arditi M., Baha I. An insertion unique to SARS-CoV-2 exhibits superantigenic character strengthened by recent mutations. bioRxiv 2020.05.21.109272. DOI: 10.1101/2020.05.21.109272Cheng M.H., Zhang S., Porritt R.A., Arditi M., Baha I. An insertion unique to SARS-CoV-2 exhibits superantigenic character strengthened by recent mutations. bioRxiv 2020.05.21.109272. DOI: 10.1101/2020.05.21.109272Rostad C.A., Chahroudi A., Mantus G., et al. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C). Pediatrics. 2020:e2020018242. DOI: 10.1542/peds.2020-018242Rostad C.A., Chahroudi A., Mantus G., et al. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C). Pediatrics. 2020:e2020018242. DOI: 10.1542/peds.2020-018242Lee W.S., Wheatley A.K., Kent S.J., et al. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020;5:1185–1191. DOI: 10.1038/s41564-020-00789-5Lee W.S., Wheatley A.K., Kent S.J., et al. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020;5:1185–1191. DOI: 10.1038/s41564-020-00789-5Gruber C., Patel R., Trachman R., et al. Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). Preprint. medRxiv. 2020;2020.07.04.20142752. DOI: 10.1101/2020.07.04.20142752Gruber C., Patel R., Trachman R., et al. Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). Preprint. medRxiv. 2020;2020.07.04.20142752. DOI: 10.1101/2020.07.04.20142752Hoepel W., Chen H.-J., Allahverdiyeva S., et al. Anti-SARSCoV-2 IgG from severely ill COVID-19 patients promotes macrophage hyper-inflammatory responses. bioRxiv 2020.07.13.190140. DOI: 10.1101/2020.07.13.190140Hoepel W., Chen H.-J., Allahverdiyeva S., et al. Anti-SARSCoV-2 IgG from severely ill COVID-19 patients promotes macrophage hyper-inflammatory responses. bioRxiv 2020.07.13.190140. DOI: 10.1101/2020.07.13.190140Carter M.J., Fish M., Jennings A., et al. Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. Nat Med 2020. DOI: 10.1038/s41591-020-1054-6Carter M.J., Fish M., Jennings A., et al. Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. Nat Med 2020. DOI: 10.1038/s41591-020-1054-6Mangalmurti N., Hunter C.A. Cytokine Storms: Understanding COVID-19. Immunity. 2020;53(1):19–25. DOI: 10.1016/j.immuni.2020.06.017Mangalmurti N., Hunter C.A. Cytokine Storms: Understanding COVID-19. Immunity. 2020;53(1):19–25. DOI: 10.1016/j.immuni.2020.06.017Consiglio C.R., Cotugno N., Sardh F., et al. The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19. Cell. 2020:S0092-8674(20)31157-0. DOI: 10.1016/j.cell.2020.09.016Consiglio C.R., Cotugno N., Sardh F., et al. The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19. Cell. 2020:S0092-8674(20)31157-0. DOI: 10.1016/j.cell.2020.09.016Lee P.Y., Day-Lewis M., Henderson L.A., et al. Distinct clinical and immunological features of SARS-COV-2-induced multisystem inflammatory syndrome in children. J Clin Invest. 2020:141113. DOI: 10.1172/JCI141113Lee P.Y., Day-Lewis M., Henderson L.A., et al. Distinct clinical and immunological features of SARS-COV-2-induced multisystem inflammatory syndrome in children. J Clin Invest. 2020:141113. DOI: 10.1172/JCI141113Diorio C., Henrickson S.E., Vella L.A., et al. Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2. J Clin Invest. 2020:140970. DOI: 10.1172/JCI140970Diorio C., Henrickson S.E., Vella L.A., et al. Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2. J Clin Invest. 2020:140970. DOI: 10.1172/JCI140970Harwood R., Allin B., Jones C.E., et al.; PIMS-TS National Consensus Management Study Group. A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. Lancet Child Adolesc Health. 2020:S2352-4642(20)30304-7. DOI: 10.1016/S23524642(20)30304-7Harwood R., Allin B., Jones C.E., et al.; PIMS-TS National Consensus Management Study Group. A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. Lancet Child Adolesc Health. 2020:S2352-4642(20)30304-7. DOI: 10.1016/S23524642(20)30304-7Henderson L.A., Canna S.W., Friedman K.G., et al. American College of Rheumatology Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 and Hyperinflammation in COVID-19. Version 1. Arthritis Rheumatol. 2020:10.1002/ art.41454. DOI: 10.1002/art.41454Henderson L.A., Canna S.W., Friedman K.G., et al. American College of Rheumatology Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 and Hyperinflammation in COVID-19. Version 1. Arthritis Rheumatol. 2020:10.1002/ art.41454. DOI: 10.1002/art.41454Elias M.D., McCrindle B.W., Larios G., et al. Management of Multisystem Inflammatory Syndrome in Children Associated with COVID-19: A Survey from the International Kawasaki Disease Registry. CJC Open. 2020 Sep 11. DOI: 10.1016/j.cjco.2020.09.004Elias M.D., McCrindle B.W., Larios G., et al. Management of Multisystem Inflammatory Syndrome in Children Associated with COVID-19: A Survey from the International Kawasaki Disease Registry. CJC Open. 2020 Sep 11. DOI: 10.1016/j.cjco.2020.09.004European Centre for Disease Prevention and Control. ECDC; Stockholm: 2020. Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children. URL: https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-risk-assessment-paediatric-inflammatory-multisystem-syndrome-15-May-2020.pdf (Date accessed: 7.07.2020).European Centre for Disease Prevention and Control. ECDC; Stockholm: 2020. Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children. URL: https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-risk-assessment-paediatric-inflammatory-multisystem-syndrome-15-May-2020.pdf (Date accessed: 7.07.2020).Grimaud M., Starck J., Levy M., et al. Acute myocarditis and multisystem inflammatory emerging disease following SARSCoV-2 infection in critically ill children. Ann Intensive Care. 2020;10(1):69. DOI: 10.1186/s13613-020-00690-8Grimaud M., Starck J., Levy M., et al. Acute myocarditis and multisystem inflammatory emerging disease following SARSCoV-2 infection in critically ill children. Ann Intensive Care. 2020;10(1):69. DOI: 10.1186/s13613-020-00690-8Toubiana J., Poirault C., Corsia A., et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ. 2020;369:m2094. DOI: 10.1136/bmj.m2094Toubiana J., Poirault C., Corsia A., et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ. 2020;369:m2094. DOI: 10.1136/bmj.m2094Chiotos K., Bassiri H., Behrens E.M., et al. Multisystem Inflammatory Syndrome in Children During the Coronavirus 2019 Pandemic: A Case Series. J Pediatric Infect Dis Soc. 2020;9(3):393–398. DOI: 10.1093/jpids/piaa069Chiotos K., Bassiri H., Behrens E.M., et al. Multisystem Inflammatory Syndrome in Children During the Coronavirus 2019 Pandemic: A Case Series. J Pediatric Infect Dis Soc. 2020;9(3):393–398. DOI: 10.1093/jpids/piaa069Riphagen S., Gomez X., Gonzalez-Martinez C., et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607–1608. DOI: 10.1016/S0140-6736(20)31094-1Riphagen S., Gomez X., Gonzalez-Martinez C., et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607–1608. DOI: 10.1016/S0140-6736(20)31094-1Belhadjer Z., Méot M., Bajolle F., et al. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation. 2020. DOI: 10.1161/CIRCULATIONAHA.120.048360Belhadjer Z., Méot M., Bajolle F., et al. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation. 2020. DOI: 10.1161/CIRCULATIONAHA.120.048360Cheung E.W., Zachariah P., Gorelik M., et al. Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City. JAMA. 2020;324(3):294–296. DOI: 10.1001/jama.2020.10374Cheung E.W., Zachariah P., Gorelik M., et al. Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City. JAMA. 2020;324(3):294–296. DOI: 10.1001/jama.2020.10374Whittaker E., Bamford A., Kenny J., et al.; PIMS-TS Study Group and EUCLIDS and PERFORM Consortia. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. JAMA. 2020;324(3):259–269. DOI: 10.1001/jama.2020.10369Whittaker E., Bamford A., Kenny J., et al.; PIMS-TS Study Group and EUCLIDS and PERFORM Consortia. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. JAMA. 2020;324(3):259–269. DOI: 10.1001/jama.2020.10369Miller J., Cantor A., Zachariah P., et al. Gastrointestinal Symptoms as a Major Presentation Component of a Novel Multisystem Inflammatory Syndrome in Children That Is Related to Coronavirus Disease 2019: A Single Center Experience of 44 Cases. Gastroenterology. 2020:S0016-5085(20)34753-3. DOI: 10.1053/j.gastro.2020.05.079Miller J., Cantor A., Zachariah P., et al. Gastrointestinal Symptoms as a Major Presentation Component of a Novel Multisystem Inflammatory Syndrome in Children That Is Related to Coronavirus Disease 2019: A Single Center Experience of 44 Cases. Gastroenterology. 2020:S0016-5085(20)34753-3. DOI: 10.1053/j.gastro.2020.05.079Feldstein L.R., Rose E.B., Horwitz S.M., et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020;383(4):334–346. DOI: 10.1056/NEJMoa2021680Feldstein L.R., Rose E.B., Horwitz S.M., et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020;383(4):334–346. DOI: 10.1056/NEJMoa2021680Capone C.A., Subramony A., Sweberg T., et al. Characteristics, Cardiac Involvement, and Outcomes of Multisystem Inflammatory Syndrome of Childhood Associated with severe acute respiratory syndrome coronavirus 2 Infection. J Pediatr. 2020;224:141–145. DOI: 10.1016/j.jpeds.2020.06.044Capone C.A., Subramony A., Sweberg T., et al. Characteristics, Cardiac Involvement, and Outcomes of Multisystem Inflammatory Syndrome of Childhood Associated with severe acute respiratory syndrome coronavirus 2 Infection. J Pediatr. 2020;224:141–145. DOI: 10.1016/j.jpeds.2020.06.044Lo M.S., Newburger J.W. Role of intravenous immunoglobulin in the treatment of Kawasaki disease. Int J Rheum Dis. 2018;21(1):64–69. DOI: 10.1111/1756-185X.13220Lo M.S., Newburger J.W. Role of intravenous immunoglobulin in the treatment of Kawasaki disease. Int J Rheum Dis. 2018;21(1):64–69. DOI: 10.1111/1756-185X.13220Wong P.H., White K.M. Impact of Immunoglobulin Therapy in Pediatric Disease: a Review of Immune Mechanisms. Clin Rev Allergy Immunol. 2016;51(3):303–314. DOI: 10.1007/s12016-015-8499-2Wong P.H., White K.M. Impact of Immunoglobulin Therapy in Pediatric Disease: a Review of Immune Mechanisms. Clin Rev Allergy Immunol. 2016;51(3):303–314. DOI: 10.1007/s12016-015-8499-2Perez E.E., Orange J.S., Bonilla F., et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immun. 2017;139:S1–46. DOI: 10.1016/j.jaci.2016.09.023Perez E.E., Orange J.S., Bonilla F., et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immun. 2017;139:S1–46. DOI: 10.1016/j.jaci.2016.09.023Prete M., Favoino E., Catacchio G., Racanelli V., Perosa F. SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial? Autoimmun Rev. 2020;19(7):102559. DOI: 10.1016/j.autrev.2020.102559Prete M., Favoino E., Catacchio G., Racanelli V., Perosa F. SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial? Autoimmun Rev. 2020;19(7):102559. DOI: 10.1016/j.autrev.2020.102559Xie Y., Cao S., Dong H., et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect. 2020;81(2):318–356. DOI: 10.1016/j.jinf.2020.03.044Xie Y., Cao S., Dong H., et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect. 2020;81(2):318–356. DOI: 10.1016/j.jinf.2020.03.044Cao W., Liu X., Bai T., et al. High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019. Open Forum Infect Dis. 2020;7(3):ofaa102. DOI: 10.1093/ofid/ofaa102Cao W., Liu X., Bai T., et al. High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019. Open Forum Infect Dis. 2020;7(3):ofaa102. DOI: 10.1093/ofid/ofaa102Diez J.-M., Romero C., Gajardo R. Currently available intravenous immunoglobulin (Gamunex®-C and Flebogamma® DIF) contains antibodies reacting against SARS-CoV-2 antigens. bioRxiv. 2020:029017. DOI: 10.1101/2020.04.07.029017Diez J.-M., Romero C., Gajardo R. Currently available intravenous immunoglobulin (Gamunex®-C and Flebogamma® DIF) contains antibodies reacting against SARS-CoV-2 antigens. bioRxiv. 2020:029017. DOI: 10.1101/2020.04.07.029017Rojas M., Rodríguez Y., Monsalve D.M., et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev. 2020;19(7):102554. DOI: 10.1016/j.autrev.2020.102554Rojas M., Rodríguez Y., Monsalve D.M., et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev. 2020;19(7):102554. DOI: 10.1016/j.autrev.2020.102554Hardy R.S., Raza K., Cooper M.S. Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases. Nat Rev Rheumatol. 2020;16(3):133–144. DOI: 10.1038/s41584-020-0371-yHardy R.S., Raza K., Cooper M.S. Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases. Nat Rev Rheumatol. 2020;16(3):133–144. DOI: 10.1038/s41584-020-0371-yStrehl C., Ehlers L., Gaber T., Buttgereit F. Glucocorticoids-allrounders tackling the versatile players of the immune system. Front Immunol. 2019;10:1744. DOI: 10.3389/fimmu.2019.01744Strehl C., Ehlers L., Gaber T., Buttgereit F. Glucocorticoids-allrounders tackling the versatile players of the immune system. Front Immunol. 2019;10:1744. DOI: 10.3389/fimmu.2019.01744Cain D.W., Cidlowski J.A. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017;17(4):233–247. DOI: 10.1038/nri.2017.1Cain D.W., Cidlowski J.A. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017;17(4):233–247. DOI: 10.1038/nri.2017.1RECOVERY Collaborative Group, Horby P., Lim W.S., et al. Dexamethasone in Hospitalized Patients with Covid-19 Preliminary Report. N Engl J Med. 2020;10.1056/NEJMoa2021436. DOI: 10.1056/NEJMoa2021436RECOVERY Collaborative Group, Horby P., Lim W.S., et al. Dexamethasone in Hospitalized Patients with Covid-19 Preliminary Report. N Engl J Med. 2020;10.1056/NEJMoa2021436. DOI: 10.1056/NEJMoa2021436Vastert S.J., Jamilloux Y., Quartier P., et al. Anakinra in children and adults with Still’s disease. Rheumatology (Oxford). 2019;58(Suppl 6):vi9–vi22. DOI: 10.1093/rheumatology/kez350Vastert S.J., Jamilloux Y., Quartier P., et al. Anakinra in children and adults with Still’s disease. Rheumatology (Oxford). 2019;58(Suppl 6):vi9–vi22. DOI: 10.1093/rheumatology/kez350Toplak N., Blazina Š., Avčin T. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives. Drug Des Devel Ther. 2018;12:1633–1643. DOI: 10.2147/DDDT.S114532Toplak N., Blazina Š., Avčin T. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives. Drug Des Devel Ther. 2018;12:1633–1643. DOI: 10.2147/DDDT.S114532Monteagudo L.A., Boothby A., Gertner E. Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome. ACR Open Rheumatol. 2020;2(5):276–282. DOI: 10.1002/acr2.11135Monteagudo L.A., Boothby A., Gertner E. Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome. ACR Open Rheumatol. 2020;2(5):276–282. DOI: 10.1002/acr2.11135Sönmez H.E., Demir S., Bilginer Y., Özen S. Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. Clin Rheumatol. 2018;37(12):3329–3335. DOI: 10.1007/s10067-018-4095-1Sönmez H.E., Demir S., Bilginer Y., Özen S. Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. Clin Rheumatol. 2018;37(12):3329–3335. DOI: 10.1007/s10067-018-4095-1Mehta P., Cron R.Q., Hartwell J., Manson J.J., Tattersall R.S. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol. 2020;2(6):e358–e367. DOI: 10.1016/S2665-9913(20)30096-5Mehta P., Cron R.Q., Hartwell J., Manson J.J., Tattersall R.S. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol. 2020;2(6):e358–e367. DOI: 10.1016/S2665-9913(20)30096-5Eloseily E.M., Weiser P., Crayne C.B., et al. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheum. 2020;72(2):326–334. DOI: 10.1002/art.41103Eloseily E.M., Weiser P., Crayne C.B., et al. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheum. 2020;72(2):326–334. DOI: 10.1002/art.41103Shakoory B., Carcillo J.A., Chatham W.W., et al. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. Crit Care Med. 2016;44(2):275–281. DOI: 10.1097/CCM.0000000000001402Shakoory B., Carcillo J.A., Chatham W.W., et al. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. Crit Care Med. 2016;44(2):275–281. DOI: 10.1097/CCM.0000000000001402Aouba A., Baldolli A., Geffray L., et al. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series [published online ahead of print, 2020]. Ann Rheum Dis. 2020;annrheumdis-2020-217706. DOI: 10.1136/annrheumdis-2020-217706Aouba A., Baldolli A., Geffray L., et al. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series [published online ahead of print, 2020]. Ann Rheum Dis. 2020;annrheumdis-2020-217706. DOI: 10.1136/annrheumdis-2020-217706Cavalli G., De Luca G., Campochiaro C., et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325e331. DOI: 10.1016/S2665-9913(20)30127-2Cavalli G., De Luca G., Campochiaro C., et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325e331. DOI: 10.1016/S2665-9913(20)30127-2Navarro-Millán I., Sattui S.E., Lakhanpal A., Zisa D., Siegel C.H., Crow M.K. Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series. Arthritis Rheumatol. 2020;10.1002/art.41422. DOI: 10.1002/art.41422Navarro-Millán I., Sattui S.E., Lakhanpal A., Zisa D., Siegel C.H., Crow M.K. Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series. Arthritis Rheumatol. 2020;10.1002/art.41422. DOI: 10.1002/art.41422Franzetti M., Pozzetti U., Carugati M., et al. Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report. Int J Infect Dis. 2020;97:215–218. DOI: 10.1016/j.ijid.2020.05.050Franzetti M., Pozzetti U., Carugati M., et al. Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report. Int J Infect Dis. 2020;97:215–218. DOI: 10.1016/j.ijid.2020.05.050Dimopoulos G., de Mast Q., Markou N., et al. Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis. Cell Host Microbe. 2020;28(1):117–123.e1. DOI: 10.1016/j.chom.2020.05.007Dimopoulos G., de Mast Q., Markou N., et al. Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis. Cell Host Microbe. 2020;28(1):117–123.e1. DOI: 10.1016/j.chom.2020.05.007Day J.W., Fox T.A., Halsey R., Carpenter B., Kottaridis P.D. Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement. Br J Haematol. 2020;190(2):e80–e83. DOI: 10.1111/bjh.16873Day J.W., Fox T.A., Halsey R., Carpenter B., Kottaridis P.D. Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement. Br J Haematol. 2020;190(2):e80–e83. DOI: 10.1111/bjh.16873Pontali E., Volpi S., Antonucci G., et al. Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. J Allergy Clin Immunol. 2020;146(1):213–215. DOI: 10.1016/j.jaci.2020.05.002.Pontali E., Volpi S., Antonucci G., et al. Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. J Allergy Clin Immunol. 2020;146(1):213–215. DOI: 10.1016/j.jaci.2020.05.002.Huet T., Beaussier H., Voisin O., et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020;2(7):e393–e400. DOI: 10.1016/S2665-9913(20)30164-8Huet T., Beaussier H., Voisin O., et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020;2(7):e393–e400. DOI: 10.1016/S2665-9913(20)30164-8Cauchois R., Koubi M., Delarbre D., et al. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19. Proc Natl Acad Sci U S A. 2020;117(32):1895118953. DOI: 10.1073/pnas.2009017117Cauchois R., Koubi M., Delarbre D., et al. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19. Proc Natl Acad Sci U S A. 2020;117(32):1895118953. DOI: 10.1073/pnas.2009017117Gagiannis D., Steinestel J., Hackenbroch C., et al. COVID-19induced acute respiratory failure: an exacerbation of organspecific autoimmunity? medRxiv 2020.04.27.20077180. DOI: 10.1101/2020.04.27.20077180Gagiannis D., Steinestel J., Hackenbroch C., et al. COVID-19induced acute respiratory failure: an exacerbation of organspecific autoimmunity? medRxiv 2020.04.27.20077180. DOI: 10.1101/2020.04.27.20077180Didier K., Bolko L., Giusti D., et al. Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians? Front Immunol. 2018;9:541. DOI: 10.3389/fimmu.2018.00541Didier K., Bolko L., Giusti D., et al. Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians? Front Immunol. 2018;9:541. DOI: 10.3389/fimmu.2018.00541Gazzaruso C., Carlo Stella N., Mariani G., et al. High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia. Clin Rheumatol. 2020;39(7):2095–2097. DOI: 10.1007/s10067-020-05180-7Gazzaruso C., Carlo Stella N., Mariani G., et al. High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia. Clin Rheumatol. 2020;39(7):2095–2097. DOI: 10.1007/s10067-020-05180-7Zhou Y., Han T., Chen J., et al. Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19. Clin Transl Sci. 2020;10.1111/cts.12805. DOI: 10.1111/cts.12805Zhou Y., Han T., Chen J., et al. Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19. Clin Transl Sci. 2020;10.1111/cts.12805. DOI: 10.1111/cts.12805

The authors declare that there are no conflicts of interest present.